KiposTech | Application Preview
KiposTech is seeking government grants to support the development of its innovative disinfection technology aimed at combating healthcare acquired infections (HAIs), which rank among the leading causes of death in the U.S. The company highlights the significant economic impact of HAIs, with annual costs exceeding $28.4 billion, plus an additional $12.4 billion due to early deaths and lost productivity. Current disinfectant solutions lack effectiveness against various pathogens linked to HAIs, prompting KiposTech to create a new non-thermal plasma photocatalytic cyclone technology, embodied in a mobile bot designed to non-selectively eliminate viruses, bacteria, fungi, and other pathogens from hospital environments.
The funding of $100,000 will advance the prototype’s development and validation over 6 to 9 months, with a clear budget allocation for research, personnel, and product testing. KiposTech aims to tap into a sizeable market worth $19.5 billion annually for medical devices, as well as a burgeoning $1 billion UV disinfection robot market projected to grow significantly in the coming years.
The application underscores the urgent need for effective disinfection solutions in hospitals to minimize infection risks and safeguard public health. KiposTech has conducted market analysis indicating a robust opportunity within the air filtration and cleaning sectors, estimating a goal of capturing 10% of the addressable healthcare market within five years.
Unlike existing solutions such as mobile UVC systems, KiposTech's PlasmaUV bot is designed to overcome limitations in disinfection efficiency, providing comprehensive cleaning capabilities without the hazardous effects of harsh chemicals. The company identifies notable competitors like Xenex and Honeywell, yet positions itself uniquely through its patented technology that addresses significant gaps in the current disinfection landscape. Overall, KiposTech seeks support to ensure its product can significantly enhance infection control and public safety in healthcare settings.
-
General Information
Business Registration Number: 7551141
Location: Columbia, PA, United States
Length of Operation: 1-5
Number of Employees: 1-10 Employees
Annual Gross Income: Less than $100k
Annual Gross Expense: $100k to $250k
Open to Loans: YES
-
Funding Usage
Healthcare acquired infections (HAIs) are 1 of the top 10 leading causes of death in the US. During the last 2.5 years of COVID-19 pandemic, HAIs thrived. The costs associated with HAIs are reported to be at least $28.4 billion each year, along with an extra societal cost of $12.4 billion from early deaths and lost productivity. To date, there is no ideal disinfectant available in the market that is proven to be effective for the various pathogens responsible for the six types of HAIs. Hence, the general claims of ’99.9% disinfection of all germs’ by many disinfectant products including the UV-C are meaningless. Our new non-thermal plasma photocatalytic cyclone technology, in the form of a bot can non-selectively disinfect viruses, bacteria, fungi, and other pathogens from hospital air, surfaces, and floor. We have determined a high clean air delivery rate with equivalent air changes per hour recommended for airborne infection control using computational fluid models. Our breadboard prototype tested at an academic partner university provides bacterial removal efficiency of up to 95% and we are also awaiting a US patent (#63405950). Our goal is to provide a healthier, pathogen free environment for hospitals, serving a total addressable market in the medical devices category of $19.5 billion per year and the newest business category of UV disinfection robot market of $1 billion per year in 2022 (alone) with 40% year over year demand forecasted for the next 5 years. With the pre-seed funding of $100,000 we plan to develop a working model of the product and validate it at an academic partner institution for its application at hospitals over a period of 6-9 months. Here is the expense breakdown, 1. R&D and prototype development: $50,000 2. Personnel: $50,000 3. Product testing at partner university: $50,000
-
Business Plan
Addressable Market of KiposTech: For purposes of addressing the current market landscape, size, annual expenditures, and growth, KiposTech analyzed the commercial opportunity that exists in today’s market for air filtration technology and surface cleaning technology, with a specific focus on medical facilities. The air filtration market is currently $10 billion per annum with a 10% annual growth rate, the medical device cleaning market is a $19.5 billion per annum market, and the newest business category is the disinfection UV robot market that is cresting $1B per annum in 2022 with 40% year over year demand signaled for the next 5 years. Year 5 target seeks capturing 10% of addressable healthcare market via product integration and licensing royalties at 6% or greater of total sales revenue across the two key product integration methodologies, robot sanitization and HVAC system integration. • With a focus on the UV robot marketplace of $600M, which will grow to $1.5B+ over 5 years, and seeking a 10% foothold in the first 3-5 years at a 6.4% licensing royalty on average producing the following conservative projected returns via licensing: PLASMAUVROBOT • Year 1 - $0 • Year 2 – 3% ------$ 1.35M • Year 3 – 5% ------$ 2.4M • Year 4 – 7.5%----$ 3.84M • Year 5 – 10% ----$ 9.6M Healthcare acquired infections (HAIs) are 1 of the top 10 leading causes of death in the US. The costs associated with HAIs are reported to be at least $28.4 billion each year, along with an extra societal cost of $12.4 billion from early deaths and lost productivity. To date, there is no ideal disinfectant available in the market that is proven to be effective for the various pathogens responsible for the six types of HAIs. Hence, the general claims of ’99.9% disinfection of all germs’ by many disinfectant products including the UV-C and HEPA filtration are meaningless. Our new non-thermal plasma photocatalytic cyclone technology, in the form of a bot can non-selectively disinfect viruses, bacteria, fungi, and other pathogens from hospital air, surfaces, and floor unlike any other technology. Our goal is to provide a healthier, pathogen free environment for hospitals, serving a total addressable market in the medical devices category of $19.5 billion per year and the newest business category of UV disinfection robot market of $1 billion per year in 2022 (alone) with 40% year over year demand forecasted for the next 5 years. We’re raising pre-seed funding and we’d love to work with ventures/private funding agencies because our product will minimize the risk of infection spread and safeguard Americans from future pandemic. Our product is timely and our initial dialogue with Europe and Asia partners assures the scope for a sustained US-global trade.
-
Self Identified Competition
1. Xenex Disinfection Services LLC 2. Honeywell International, Inc. 3. Plasma Air Alternate non-touch disinfection methods such as the mobile UVC systems have gained attention as a popular cleaning and disinfection approach in hospitals and other buildings. However, UVC systems cannot disinfect areas out of their line of sight. Further, the microbial sensitivity varies widely to the UV radiation, and the UV dose needed for bacterial disinfection cannot be applied to disinfect hardy fungal spores, antibiotic resistant genes, and the viruses. The mechanical ventilation in hospitals is designed for comfort and not infection control. The disinfectants used at hospitals are harsh and have hazardous adverse effects. To date, there is no ideal disinfectant available in the market that is proven to be effective for the various pathogens responsible for causing the serious healthcare acquired infections. To fulfill this technology gap and to mitigate the infection spread, we are introducing a new mobile disinfection system called the ‘PlasmaUV bot’ that utilizes non-thermal plasma photocatalytic cyclone and jet technology for complete, air, floor, and surface cleaning. No such technology is available on the market.
-
Contact Applicant
Subscribe to our Administrator Dashboard to gain full access to this application. Learn More
